On January 5, 2022, Health Canada amended their Food and Drug Regulations to allow practitioners to request access to previously prohibited drugs such as psilocybin, MDMA, and other psychedelic treatments through a new Special Access Program (SAP).
The amendment which reversed a policy from 2013 that prohibited special access to restricted drugs was seen as a watershed moment for the psychedelics industry.
Only months later on March 21, 2022, Dr. Valorie Masuda MD received authorization to treat six patients experiencing end-of-life distress with psilocybin and psychotherapy in what is the first known case of psilocybin being accessed through Canada’s SAP.
Share this post
